Document Detail

Plasma carnitine levels as a marker of impaired left ventricular functions.
MedLine Citation:
PMID:  11129956     Owner:  NLM     Status:  MEDLINE    
L-Carnitine plays a role in the utilization of fatty acids and glucose in the myocardium. Previous studies have indicated carnitine deficiency in patients with congestive heart failure. However, the extent of altered carnitine metabolism and left ventricular function is not fully determined. This study is designed to determine if plasma L-carnitine levels can serve as a marker for impaired left ventricular function in patients with congestive heart failure. To test this hypothesis, plasma and urinary levels of L-carnitine were measured in 30 patients with congestive heart failure (CHF) and in 10 control subjects. CHF was due to dilated cardiomyopathy (DCM) and rheumatic heart disease (RHD). Cardiac functions such as percentage of fractional shortening (%FS), ejection fraction (EF), left ventricular mass index (LVMI), were determined by echocardiography. All patients and control subjects had normal renal functions. Plasma carnitine was significantly higher in patients with DCM (37.05+/-7.62, p < 0.0001) and with RHD (47.2+/-8.04, p < 0.0001) vs. the control subjects (14.4+/-5.30 mg/L). Urinary carnitine was significantly higher in DCM (49.13+/-14.11, p < 0.0001) and in RHD 43.53+/-15.5, p < 0.0001), than the control (25.1+/-5.78 mg/L). Plasma carnitine level correlated significantly with impaired left ventricular systolic functions in these patients: % FS < 25 % (r = -0.38 and p = 0.038), EF < 0.55 (r = -0.502 and p = 0.005) and LMVI > 124 gm/m2 (r = 0.436, and p = 0.016). These data suggest that elevated plasma and urinary carnitine levels in patients with CHF could serve as a marker for myocardial damage and impaired left ventricular functions.
W El-Aroussy; A Rizk; G Mayhoub; S A Aleem; S El-Tobgy; M S Mokhtar
Related Documents :
8803436 - Congestive heart failure revisited: new concepts in treatment.
7012816 - Chronic congestive heart failure. eight steps in management.
19641696 - Echocardiography predicts adverse cardiac remodelling in heart failure.
20152246 - Effect of right ventricular function and venous congestion on cardiorenal interactions ...
7654946 - Time-frequency analysis of ecg for late potentials in sudden cardiac death survivors an...
22544366 - Meta-analysis identifies six new susceptibility loci for atrial fibrillation.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Molecular and cellular biochemistry     Volume:  213     ISSN:  0300-8177     ISO Abbreviation:  Mol. Cell. Biochem.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-12-20     Completed Date:  2001-02-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0364456     Medline TA:  Mol Cell Biochem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  37-41     Citation Subset:  IM    
Department of Cardiology, Cairo University, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood,  urine
Cardiomyopathy, Dilated / complications
Carnitine / blood*,  urine
Heart Failure / blood,  etiology,  physiopathology*,  urine
Middle Aged
Rheumatic Heart Disease / complications
Ventricular Dysfunction, Left / blood,  diagnosis*,  urine
Reg. No./Substance:
0/Biological Markers; 541-15-1/Carnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Study on the relationship between calcium-induced calcium release from mitochondria and PTP opening.
Next Document:  Role of endogenous regucalcin in protein tyrosine phosphatase regulation in the cloned rat hepatoma ...